The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Drugs & Targets

FDA grants de novo clearance to Sonablate 450 for prostate tissue

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

FDA granted de novo clearance to SonaCare Medical LLC to market the Sonablate 450 in the U.S. for the ablation of prostate tissue.

Sonablate is the first High Intensity Therapeutic Ultrasound device to receive FDA regulatory authorization for prostate tissue ablation. SonaCare expects to begin U.S. distribution this October.

Sonablate is the Company’s second medical device to receive U.S. FDA regulatory authorization, complementing the 510(k) cleared Sonatherm laparoscopic HITU ablation device.

Table of Contents

YOU MAY BE INTERESTED IN

Clinical

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

The long-awaited results from the RASolute 302 trial—a phase III clinical trial evaluating daraxonrasib, a RAS inhibitor, for the treatment of patients with previously treated, metastatic pancreatic ductal adenocarcinoma—have been read out. 
By Jacquelyn Cobb
Cancer History ProjectEditorial

Calabresi’s “Cancer at a Crossroads” report was the first step toward historic doubling of the NIH budget
Fox Chase’s Winn contemplates Crossroads 2.0

At a lecture at Yale Cancer Center recently, Robert A. Winn brandished a copy of a 32-year old booklet titled “Cancer at a Crossroads: A Report to Congress for the Nation,” using it as a show-and-tell prop in arguing that America’s cancer program is once again at a crossroads and therefore in urgent need of strategic thinking (The Cancer Letter, April 10, 2026).
By Paul Goldberg
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account